The focus of the study is on patients Parkinson's disease showing as well behavioral disorders that can be described as pathological and are summarized under the term impulse control disorder (ICD). Changes in behavior and also pathological disorders are a common side effect of treatment for Parkinson's disease. The goal of this academic study is to compare the effect of surgical (deep brain stimulation, DBS) treatment combined with a coordinated and adapted best medical treatment (BMT) to be compared with the effect of optimized best medical treatment (BMT) alone. The stimulation arm (DBS+BMT) as well as the medication arm (BMT only) will be monitored according to clinical routine. Participants will have to agree to be randomly assigned to either deep brain stimulation in combination with the best medical treatment (DBS group) or the best medical treatment alone (BMT group). Participants will have to come regularly according to clinical routine to the clinic and complete various questionaires and scales for the study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
60
according to widely accepted expert consensus paper
according to (Debove et al (2024), 'Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus, Mov Disord.
University Hospital Cologne
Cologne, Germany
RECRUITINGUniversity Hospital Carl Gustav Carus
Dresden, Germany
RECRUITINGUniversity Hospital Duesseldorf
Düsseldorf, Germany
RECRUITINGUniversity Medical Center Hamburg-Eppendorf
Hamburg, Germany
RECRUITINGUniversity Hospital Schleswig-Holstein (UKSH), Campus Kiel
Kiel, Germany
RECRUITINGUniversity Hospital of Giessen and Marburg (UKGM), Campus Marburg
Marburg, Germany
RECRUITINGCharité Campus Mitte
Mitte, Germany
RECRUITINGUniversity Hospital Tuebingen
Tübingen, Germany
RECRUITINGUniversity Hospital Wuerzburg
Würzburg, Germany
RECRUITINGAmsterdam University Medical Center
Amsterdam, Netherlands
RECRUITING...and 2 more locations
Ardouin Scale of Behaviour in Parkinson's Disease (ASBPD)
Difference of change (improvement) from baseline to follow-up between the two treatment groups with respect to the hyperdopaminergic sub-score
Time frame: 12 months
Questionnaire for Impulsive-Compulsive Disorders in Parkinson Disease Rating Scale (QUIP RS)
Difference of change (improvement) from baseline to follow-up between the two treatment groups
Time frame: 12 months
Starkstein-Apathy-Scale (SAS)
Difference of change (improvement) from baseline to follow-up between the two treatment groups
Time frame: 12 months
Hospital Anxiety and Depression Scale (HADS)
Difference of change (improvement) from baseline to follow-up between the two treatment groups
Time frame: 12 months
Beck Depression Inventory (BDI)
Difference of change (improvement) from baseline to follow-up between the two treatment groups
Time frame: 12 months
suicidal item 9 of the BDI
safety focus on suicidal item 9 of the BDI with reference to the question for the last 2 months
Time frame: 12 months
Neuropsychiatric-fluctuations scale (NFS)
Difference of change (improvement) from baseline to follow-up between the two treatment groups
Time frame: 12 months
Young mania rating scale (YMRS)
Difference of change (improvement) from baseline to follow-up between the two treatment groups
Time frame: 12 months
Quality of life (PDQ-39) measured by Parkinson Disease Questionaire-39 Summary Index
Difference of change (improvement) from baseline to follow-up between the two treatment groups
Time frame: 12 months
Zarit Burden Interview ( ZIB) for the change of burden assessment in caregivers using the brief version
Difference of change (improvement) from baseline to follow-up between the two treatment groups
Time frame: 12 months
MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) (parts I-IV med on/med off and stim on/stim off; if applicable
Difference of change (improvement) from baseline to follow-up between the two treatment groups
Time frame: 12 months
Marconi Dyskinesia Rating Scale
Difference of change (improvement) from baseline to follow-up between the two treatment groups
Time frame: 12 months
Levodopa-equivalent/dopamine-agonist dosage (LEDD) and other medication
Difference of change (improvement) from baseline to follow-up between the two treatment groups
Time frame: 12 months
Pittsburgh Sleep Quality Index (PSQI)
Difference of change (improvement) from baseline to follow-up between the two treatment groups
Time frame: 12 months
Safety weight monitoring (BMI control)
Difference of change from baseline to follow-up between the two treatment groups
Time frame: 12 months
Montreal Cognitive Assessment (MoCA)
Difference of change (improvement) from baseline to follow-up between the two treatment groups
Time frame: 12 months
Clinical Global Impression (CGI-S, Severity) (CGI-C, Change)
Difference of change (improvement) from baseline to follow-up between the two treatment groups
Time frame: 12 months
Patient Global Impression (PGI-S, Severity) (PGI-C, Change)
Difference of change (improvement) from baseline to follow-up between the two treatment groups
Time frame: 12 months
Parkinson's disease Dysarthria Compound Score (PD-DCS) (Speech assessment)
Difference of change (improvement) from baseline to follow-up between the two treatment groups
Time frame: 12 months
Adverse events
Reporting and analysis of adverse events: Frequency, type and severity of therapy related relevant adverse events of medication or DBS
Time frame: 12 months
Parkinson's disease Dysarthria Compound Score (PD-DCS)
An intra-group comparison will be performed between the individual patient's safety speech outcome of Parkinson's disease Dysarthria Compound Score (PD-DCS) The PD-DCS is a speech acoustic summary measure of the main speech affected domains in PD, namely monopitch, monoloudness, imprecise consonants, inappropriate silences, harsh/breathy voice, and speech timing abnormalities. Acoustic proxy measures of these perceptual speech domains can be extracted from speech using modern acoustic speech analysis.
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.